A Phase II Study of Rituximab (IND#7028) and Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy in Children With Recurrent/Refractory B-cell (CD20+) Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rituximab (Primary) ; Carboplatin; Cytarabine; Etoposide; Filgrastim; Ifosfamide; Methotrexate
- Indications Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 08 Oct 2013 Biomarkers information updated
- 07 Oct 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 07 Oct 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.